| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Corticosteroid Receptor[1]
Ocedurenone is a potent and selective antagonist of the mineralocorticoid receptor (MR). It selectively binds to MR with higher affinity than to glucocorticoid, progesterone, or androgen receptors. By blocking MR activation, it reduces high blood pressure, inflammation, and fibrosis in the kidneys. |
|---|---|
| ln Vitro |
An antagonist of corticosteroid receptors is ocedurenone[1].
In vitro studies show Ocedurenone is a potent corticosteroid receptor blocker.Its high selectivity for MR over other steroid hormone receptors is crucial for its antihypertensive and renal protective effects without the hormonal side effects seen with less selective antagonists. |
| ln Vivo |
In vivo, Ocedurenone shows dose-dependent efficacy in reducing systolic blood pressure (SBP) in animal models. In a Phase 2b clinical trial (BLOCK-CKD), it demonstrated a significant dose-dependent reduction in SBP from baseline compared to placebo in patients with advanced CKD and uncontrolled hypertension.
|
| Enzyme Assay |
Cell-free assays use purified mineralocorticoid receptors (MR). A radioligand binding assay is performed using 3H-aldosterone and varying concentrations of Ocedurenone. The mixture is incubated at 4degC to reach equilibrium. The bound and free radioligands are separated, and the half-maximal inhibitory concentration (IC50) and Ki are calculated to determine its receptor binding affinity.
|
| Cell Assay |
Cellular assays are performed in cells expressing the mineralocorticoid receptor. A reporter gene assay is used where a luciferase gene is under the control of an aldosterone-responsive element. Ocedurenone is added, and the reduction in aldosterone-induced luciferase activity is measured to confirm its antagonistic function in a cellular context.
|
| Animal Protocol |
Animal studies are conducted in rodent models of hypertension, such as the DOCA-salt rat model. Ocedurenone is administered orally once daily. Blood pressure is measured via telemetry or tail-cuff plethysmography. Renal function (creatinine clearance), markers of kidney injury (proteinuria), and tissue histology are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetics: Ocedurenone is orally bioavailable. It is primarily metabolized by CYP3A4. Co-administration with strong CYP3A inhibitors (itraconazole) increased its AUC by 104%, while strong CYP3A inducers (rifampin) decreased its AUC by 84%, indicating significant drug-drug interaction potential.
|
| Toxicity/Toxicokinetics |
In Phase 2b clinical trials (BLOCK-CKD), Ocedurenone was generally well-tolerated. The most common adverse events were mild to moderate and related to potassium levels (hyperkalemia), a known effect of MRAs. No significant safety signals regarding hepatotoxicity or severe adverse events were reported at the tested doses.
|
| References | |
| Additional Infomation |
Ocedurenone is a small molecule drug. The prefix "-renone" in its International Nonproprietary Name (INN) indicates that Ocedurenone is a mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonist. Ocedurenone is currently being investigated in the clinical trial NCT04968184 (Efficacy and safety of KBP-5074 in the treatment of uncontrolled hypertension and moderate to severe chronic kidney disease (CKD)). The monoisotopic molecular weight of Ocedurenone is 503.21 Da.
Ocedurenone has completed a Phase 2b trial (BLOCK-CKD) and is being further investigated in a Phase 3 trial (CLARION-CKD) for treating patients with stage 3b/4 CKD and uncontrolled hypertension. It represents a promising new generation of non-steroidal MRAs with high selectivity and organ-protective effects. |
| Molecular Formula |
C28H30CLN5O2
|
|---|---|
| Molecular Weight |
504.023105144501
|
| Exact Mass |
503.208
|
| CAS # |
1359969-24-6
|
| PubChem CID |
75593324
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
36
|
| Complexity |
905
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(#N)C1=CC=C(N2[C@@H](C3CCCC3)[C@@]3([H])CCC4=C(C3=N2)C=CC(C(N2CCC(O)CC2)=O)=N4)C=C1Cl
|
| InChi Key |
UXHQLGLGLZKHTC-CUNXSJBXSA-N
|
| InChi Code |
InChI=1S/C28H30ClN5O2/c29-23-15-19(6-5-18(23)16-30)34-27(17-3-1-2-4-17)22-8-9-24-21(26(22)32-34)7-10-25(31-24)28(36)33-13-11-20(35)12-14-33/h5-7,10,15,17,20,22,27,35H,1-4,8-9,11-14H2/t22-,27-/m0/s1
|
| Chemical Name |
4-[(3S,3aR)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (~198.4 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.96 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9840 mL | 9.9202 mL | 19.8405 mL | |
| 5 mM | 0.3968 mL | 1.9840 mL | 3.9681 mL | |
| 10 mM | 0.1984 mL | 0.9920 mL | 1.9840 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
